M. Božič-Mijovski

Ex vivo neutralization of unfractionated heparin for assessing overall haemostatic potential in patient plasma.

A. Blinc, M. Stegnar, V. Boc, 2015, Thrombosis research.

Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation

R. Malmström, J. Antovic, A. Mavri, 2019, European Journal of Clinical Pharmacology.

Is Restenosis/Reocclusion after Femoropopliteal Percutaneous Transluminal Angioplasty (PTA) the Consequence of Reduced Blood Flow, Inflammation, and/or Hemostasis Disturbances?

A. Blinc, M. Stegnar, V. Salapura, 2015 .

Association of Haemostasis Activation Markers with Thrombophilia and Venous Thromboembolism

M. Kozak, M. Stegnar, A. Antovic, 2011 .

2. Measuring hypercoagulability as a risk factor for cardiovascular diseases

M. Božič-Mijovski, M. Božič-Mijovski, 2016 .

Dabigatran Concentration: Variability and Potential Bleeding Prediction In “Real–Life” Patients With Atrial Fibrillation

R. Malmström, J. Antovic, A. Mavri, 2015, Basic & clinical pharmacology & toxicology.

Hyperhomocysteinemia and thrombophilia

M. Božič-Mijovski, M. Božič-Mijovski, 2010, Clinical chemistry and laboratory medicine.

Increased Coagulation and Decreased Fibrinolysis as Measured with Overall Hemostatic Potential Are Dependent on BMI and Not Associated with PCOS.

A. Janež, M. Jensterle, M. Božič-Mijovski, 2017, Metabolic syndrome and related disorders.